Skip to main content

Copyright and Access to Taxpayer Funded Research

This is the third post in a series on copyright in medicine. We started off the series with two posts. The first discussed the importance of a NEJM article advocating for the greater use of copyleft licenses in medicine. The second detailed the dubious copyright infringement claims by the authors and owners of the mini-mental state exam. This last post in the series is a call for help maintain a bare minimum of open access to taxpayer funded research.

A new Association of American Publishers (AAP) backed bill titled the “Research Works Act” is threatening the currnet National Institutes of Health (NIH) public access policy. The current NIH policy requires that all final peer-reviewed journal manuscripts that arise from NIH funds be submitted to PubMed Central upon acceptance for publication, and that these papers are accessible to the public on PubMed Central no later than 12 months after publication.

Despite an overly restrictive period of up to 12 months before making these works open to the public, Representatives Carolyn Maloney (D-NY) and Darrell Issa (R-CA) have decided to move forward with a bill that would effectively end open access to work funded by the federal government.  The language of the bill is simple in its destructive power:
"No Federal agency may adopt, implement, maintain, continue, or otherwise engage in any policy, program, or other activity that:  
(1) causes, permits, or authorizes network dissemination of any private-sector research work without the prior consent of the publisher of such work;  

 (2) requires that any actual or prospective author, or the employer of such an actual or prospective author, assent to network dissemination of a private-sector research work (i.e any non-governmental agency like a university). 

Many journalists and bloggers have been up in arms over this issue.  Major outlets including Scientific American, WIRED, and the Atlantic, have had articles lambasting the bill.  So, what can be done?  Michael Eisen from UC Berekely said the following in his blog post:
“It is inexcusable that a simple idea – that no American should be denied access to biomedical research their tax dollars paid to produce – could be scuttled by a greedy publisher who bought access to a member of Congress.” [Referring to political contributions that Dutch publisher Elsevier made to Rep Maloney] 

He goes on to urge his readers to:
“call/write/email/tweet Representative Maloney today, and tell her you support taxpayer access to biomedical research results. Ask her why she wants cancer patients to pay Elsevier $25 to access articles they’ve already paid for. And demand that she withdraw H.R. 3699."
By far the easiest thing anyone reading this post can do is to start off by tweeting Rep Maloney at  either @RepMaloney or @CarolynBMaloney.  I would also strongly encourage you to tweet Rep Issa at @darrellissa, as he proudly proclaims himself to be for "an #OPEN, accessible & uncensored internet" (makes you wonder why he proposes cutting off open access to journal articles).

Deevy Bishop, from BishopBlog, takes it one step further with a call to arms for her academic colleagues:
“We provide the articles for Elsevier journals, and we do a lot of unpaid work reviewing and editing for them. None of us wants to restrict our opportunities for publishing, but these days there are a lot of outlets available. When deciding where to submit a paper, I suspect that most academics, like me, take little notice of who the publisher of a journal is. I focus more on whether the journal has a good editor, my prior experience of publication lags, and whether Open Access is available. But as from now, I shall include publisher in the criteria I adopt, and avoid Elsevier as far as I can. Also, if asked to review for a journal, I’ll check if it is in the Elsevier stable, using this handy website, and if so, I’ll explain why I’m not prepared to review. I suggest that if you are as annoyed as I am by this story, you do likewise, and refuse to engage with Elsevier journals.” 

I probably wouldn't go as far as Deevy Bishop and I don't think it is fair to single out Elsevier, but it does make me think of all the free labor that I willing give to these journals.   A similar option is to take a "don't peer-review articles from non-open access journals" approach as seen in this letter by Michael Ashburner posted on Casey Bergman’s blog.

Lastly, you can make your voice heard also to the the National Science and Technology Council's Task Force on Public Access to Scholarly Publications. There is a Request for Information (RFI) on the Federal Register's website that closes on January 12 (ignore the date on the website, the deadline was extended).  This is not part of the bill, but it is another way to get your voice heard.

If you don’t know what to say for the RFI or in the letters to your representative, look at this link from the Provost of Harvard University, Alan M. Garber.   Alternatively, you can also just ask for the bare minimum of open access protect as suggested by Stevan Harnad:

(i) the fundee’s revised, accepted refereed final draft 
(ii) of all refereed journal articles (including refereed conference articles) resulting from the funded research must be 
(iii) deposited immediately upon acceptance for publication 
(iv) in the fundee’s institutional repository. 
(v) Access to the deposit must be made gratis OA (online access free for all) immediately (no OA embargo) wherever possible (over 60 % of journals already endorse immediate gratis OA self-archiving).

By Eric Widera (@ewidera)

Addendum: for an excellent round-up of blog posts on this subject go to John Dupuis' blog.


Certainly, research funded by public funds should be freely available to the public. However, the fact is that medical publishing today is a hugely profitable enterprise run by greedy business people and not by professionals interested in advancing scientific discovery or public health. What other business obtains its raw materials at no cost (medical articles, in this case), has a large cadre of unpaid, slave labor at its command (eg, peer reviewers) and then charges the public outlandish fees for the finished product (eg, in some cases >$50 USD for an individual article of from 1 to 15 electronic pages)?

And, with so many competing enterprises of this nature, is it any wonder that medical journals are filled with studies of dubious quality and little validity; eg, underpowered trials with diminutive but statistically significant effect sizes? In my opinion -- as a researcher/writer -- 90% of what is published in the medical literature these days is overly biased and cannot be trusted as valid. The editors should hang their heads in shame and the public (professionals and all other consumers of the literature) should make their displeasure known by not scribing to or purchasing such drivel.

Popular posts from this blog

The Future of Palliative Care: A Podcast with Diane Meier

There are few names more closely associated with palliative care than Diane Meier.  She is an international leader of palliative care, a MacArthur "genius" awardee, and amongst many other leadership roles, the CEO of the Center to Advance Palliative Care (CAPC).  We were lucky enough to snag Diane for our podcast to talk about everything we always wanted to ask her, including:
What keeps her up at night?Does palliative care need a national strategy and if so why and what would it look like?The history of CAPC and the leadership centersAdvice that she has for graduating fellows who want to continue to move palliative care forward as they start their new careersWhat she imagines palliative care will look like in 10 or 15 years?What is the biggest threat facing palliative care? So take a listen and if you want to dive a little deeper, here are two articles that we discussed during the podcast:
A National Strategy For Palliative Care. Health Affairs 2017Palliative Care Leadership…

Elderhood: Podcast with Louise Aronson

In this week's podcast we talk with Louise Aronson MD, MFA, Professor of Geriatrics at UCSF about her new book Elderhood, available for purchase now for delivery on the release date June 11th.

We are one of the first to interview Louise, as she has interviews scheduled with other lesser media outlets to follow (CBS This Morning and Fresh Air with Terry...somebody).

This book is tremendously rich, covering a history of aging/geriatrics, Louise's own journey as a geriatrician facing burnout, aging and death of family of Louise's members, insightful stories of patients, and more.

We focus therefore on the 3 main things we think our listeners and readers will be interested in.

First - why the word "Elder" and "Elderhood" when JAGS/AGS and others recently decided that the preferred terminology was "older adult"?

Second - Robert Butler coined the term ageism in 1969 - where do we see ageism in contemporary writing/thinking?  We focus on Louise's…

Psychedelics: Podcast with Ira Byock

In this week's podcast, we talk with Dr. Ira Byock, a leading palliative care physician, author, and public advocate for improving care through the end of life.

Ira Byock wrote a provocative and compelling paper in the Journal of Pain and Symptom Management titled, "Taking Psychedelics Seriously."

In this podcast we challenge Ira Byock about the use of psychedelics for patients with serious and life-limiting illness.   Guest host Josh Biddle (UCSF Palliative care fellow) asks, "Should clinicians who prescribe psychedelics try them first to understand what their patient's are going through?" The answer is "yes" -- read or listen on for more!

While you're reading, I'll just go over and lick this toad.


You can also find us on Youtube!

Listen to GeriPal Podcasts on:
iTunes Google Play MusicSoundcloudStitcher
Eric: Welcome to the GeriPal Podcast. This is Eric Widera.

Alex: This is Alex Smith.

Eric: Alex, I spy someone in our …